Pharming Group N.V.
NASDAQ:PHARBiotechnology
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
Volume 0.01M
Average 0.01M
PHAR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Pharming Group N.V.NASDAQ: PHAR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q1 FY2026 research & development of $25.56M rose 20.9% year over year, behind the +22.1% change in trailing-twelve-month research & development. Sequentially, it fell 20.3% from the prior quarter. Over 3 fiscal years it compounded at +23.1% a year.
Context
- Research & development amounted to 26.0% of revenue in FY2025, down 2.0 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.9% toward the trailing-twelve-month pace of +22.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 98.08M USD
- Year-over-year change
- +13.9%
- 4-year CAGR
- +5.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.08M | +13.9% |
| FY2024 | 2024-12-31 | 86.1M | +24.9% |
| FY2023 | 2023-12-31 | 68.91M | +31.2% |
| FY2022 | 2022-12-31 | 52.53M | -34.2% |
| FY2021 | 2021-12-31 | 79.78M | — |
Research & Development vs competitors
How PHAR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +22.1% is the 3rd highest of 9, against a peer median of +9.8%.
- Research & development amounts to 28.3% of revenue for PHAR, versus a peer median of 329.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $181.1B USD | +19955.1% | +12.4% | 17.6% | |
| LTM Sep 2026 | $923.16M USD | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $361.17M USD | -21.5% | -2.5% | 546.5% | |
| LTM Jun 2026 | $197.76M USD | +15.5% | -13.1% | 21.0% | |
| LTM Mar 2026 | $144.07M USD | +45.7% | +21.0% | 449.1% | |
| LTM Mar 2026 | $137.53M USD | -14.3% | -5.0% | — | |
| LTM Sep 2026 | €132.22M EUR | +7.0% | +29.5% | — | |
| LTM Mar 2026 | $104.71M USD | +22.1% | +23.1% | 28.3% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| Peer median (excluding PHAR) | — | +9.8% | +3.2% | 329.9% | |
Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 225.46M | 205.62M | 245.32M | 307.75M | 377.18M |
| Cost of Revenue | 23.97M | 17.56M | 25.21M | 36.66M | 45.63M |
| Gross Profit | 201.49M | 188.06M | 220.1M | 271.09M | 331.56M |
| Gross Margin | 89.4% | 91.5% | 89.7% | 88.1% | 87.9% |
| Research & Development | 79.78M | 52.53M | 68.91M | 86.1M | 98.08M |
| Selling, General & Admin | 54.56M | 68.85M | 87.5M | 102.74M | 117.44M |
| Operating Expenses | 186.12M | 169.83M | 225.49M | 280.02M | 309.75M |
| Depreciation & Amortization | 22.23M | 13.19M | 15.93M | 16.64M | 10.76M |
| EBITDA | 55.3M | 33.53M | 9.88M | 16.89M | 31.7M |
| EBITDA Margin | 24.5% | 16.3% | 4.0% | 5.5% | 8.4% |
| Operating Income | 15.37M | 18.23M | (5.39M) | (8.93M) | 20.88M |
| Operating Margin | 6.8% | 8.9% | -2.2% | -2.9% | 5.5% |
| Interest Income | 59.99K | 85K | 3.53M | 5.92M | 2.56M |
| Interest Expense | 7M | 5.36M | 5.96M | 9.05M | 21.31M |
| Other Income / Expenses | 10.79M | (3.25M) | (6.63M) | 133.58K | (8.03M) |
| Income Before Tax | 26.16M | 14.99M | (12.01M) | (8.79M) | 12.88M |
| Pre-Tax Margin | 11.6% | 7.3% | -4.9% | -2.9% | 3.4% |
| Income Tax Expense | 8.03M | 1.31M | (1.46M) | 3.47M | 10.34M |
| Net Income | 18.13M | 13.67M | (10.55M) | (12.26M) | 2.86M |
| Net Margin | 8.0% | 6.7% | -4.3% | -4.0% | 0.8% |
| EPS (Basic) | 0.23 | 0.17 | (0.14) | (0.18) | 0.04 |
| EPS (Diluted) | 0.21 | 0.16 | (0.14) | (0.18) | 0.04 |
| Weighted Avg Shares | 87.64M | 82.54M | 65.7M | 68.92M | 71.32M |
| Weighted Avg Shares (Diluted) | 87.64M | 84.28M | 65.7M | 68.92M | 71.32M |
Pharming Group N.V.
NASDAQ:PHAR
Intrinsic Alpha fair value
Locked
Current Price
$12.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.